Genezen

Indianapolis, IN · Lexington, MA
Find alternatives to Genezen for AAV →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
78.1
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ○ SEC Filings ✓ Press (6) ○ EMA GMP ○ MHRA GMP ✓ HC GMP (1)

Quick Facts: Genezen

Signal Score
78.1/100 (as of 2026-10-29)
Quality Compliance
100.0/100
Headquarters
Indianapolis, IN · Lexington, MA
Modalities
AAV, Lentiviral
Active Programs
No ClinicalTrials.gov matches confirmed — 2 partnership signals in press (announcements, not verified)
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Genezen

Mid-tier AAV/lentiviral specialist.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-08-27)
Most Recent HC OutcomeCompliant · 2025-08-20
HC Attribution1 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 2 partnership announcements found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Indianapolis, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
StatusAvailable
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Indianapolis, IN
Press Signals6 articles (not scored)
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100

Genezen FDA Inspection History

2025-08
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-08-27
GENEZEN MA, INC.
Lexington, Massachusetts Facility-linked
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Hiring Activity 26 open roles Beta

From public job postings on Genezen's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
26
open roles
24
in manufacturing, quality, PD/MSAT, engineering or regulatory (92%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 1 new posting, 0 taken down.
What this may mean
  • 8 of the 20 openings at Lexington, MA are in quality (QA/QC). That fits added testing or batch-release work, but it can also be normal turnover.
By function
Manufacturing & operations 10
Quality (QA / QC) 9
Process development & MSAT 4
Engineering & facilities 1
Commercial, BD & client projects 1
Other (finance, HR, IT, other) 1
By site
Lexington, MA profile site
7 mfg/ops · 8 QA/QC · 3 PD/MSAT · 1 eng. · 1 other
20
Indianapolis, IN profile site
3 mfg/ops · 1 QA/QC · 1 PD/MSAT · 1 other
6
Modality words in job titles
Biologics (cell culture, USP/DSP)3
Notable roles
Director/Sr. Director, Quality Assurance Operations Senior operations / quality role · Lexington, MA
Sr. Manager/Assoc Director, Manufacturing Sciences & Technology (MSAT) Senior operations / quality role · Lexington, MA
Latest postings
Indirect Procurement & Strategic Sourcing Lead Manufacturing & operations · Lexington, MA · posted Nov 19, 2026
Sr/Lead Validation Engineer Quality (QA / QC) · Lexington, MA · posted Nov 17, 2026
Manager, Operational Excellence & Continuous Improvement Manufacturing & operations · Lexington, MA · posted Nov 16, 2026
QA Specialist II 3:00pm-11:30pm) Quality (QA / QC) · Lexington, MA · posted Aug 10, 2026
Lead Engineer, Manufacturing Sciences & Technology (MSAT) Process development & MSAT · Lexington, MA · posted Nov 9, 2026
Sr. Manager/Assoc Director, Manufacturing Sciences & Technology (MSAT) Process development & MSAT · Lexington, MA · posted Oct 30, 2026
Manager, Continuous Improvement & Human Performance Manufacturing & operations · Lexington, MA · posted Oct 26, 2026
Director/Sr. Director, Quality Assurance Operations Quality (QA / QC) · Lexington, MA · posted Oct 22, 2026
Manager/Senior Manager, Quality Control - Microbiology Quality (QA / QC) · Lexington, Massachusetts · posted Oct 21, 2026
Material Handler Manufacturing & operations · Indianapolis, Indiana · posted Oct 16, 2026
Manufacturing Technician II/III - Buffer Prep (2nd Shift, 3pm-11:30pm) Manufacturing & operations · Lexington, MA · posted Oct 10, 2026
Scientist I, Analytical Development Process development & MSAT · Lexington, MA · posted Sep 28, 2026
Coverage: counted from Genezen's own careers board. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: job-boards.greenhouse.io · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 6 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-10-14
Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial | Newswise - Newswise
Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial | Newswise  Newswise
general 2026-10-06
InterAct Taps Genezen to Advance Breast Cancer AAV8 Gene Therapy to Clinic - GenomeWeb
InterAct Taps Genezen to Advance Breast Cancer AAV8 Gene Therapy to Clinic  GenomeWeb
general 2026-10-05
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer | Newswise - Newswise
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer | Newswise  Newswise
general 2026-10-05
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer - PR Newswire
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer  PR Newswire
partnership 2026-09-29
Genezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2 | Newswise - Newswise
Genezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2 | Newswise  Newswise
partnership 2026-09-29
Genezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2 - PR Newswire
Genezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2  PR Newswire

Frequently Asked Questions About Genezen

How many FDA inspections does Genezen have on record?
CDMO Signal tracks 1 FDA inspection for Genezen, sourced from the FDA inspection database. See the full inspection history above.
Has Genezen received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Genezen.
What is Genezen's CDMO Signal Score?
Genezen has a Signal Score of 78/100, based on quality, operations, financial stability, and capacity data.
Evaluating Genezen for a manufacturing program?
Use the free AI matchmaker to compare Genezen against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs →

Similar CDMOs

Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
BioReliance (Merck)
Glasgow, UK · Rockville, MD
Signal Score: 80.3
AAV, Lentiviral, Biologics
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation

Compare Genezen with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Genezen
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.